W F Riesen
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Jörger M, Templeton A, Köberle D, Engler H, Riesen W, Thürlimann B. Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates. Cancer Chemother Pharmacol 2010
04.08.2010Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
04.08.2010Cancer Chemother Pharmacol 2010
Jörger Markus, Templeton Arnoud, Köberle Dieter, Engler H, Riesen W F, Thürlimann Beat
Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
Jörger M, Riesen W, Thürlimann B. Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer. J Oncol Pharm Pract 2010
28.07.2010Bevacizumab-associated hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal breast cancer
28.07.2010J Oncol Pharm Pract 2010
Jörger Markus, Riesen W F, Thürlimann Beat
Hypertriglyceridemia as a possible risk factor for prostate cancer
Wuermli L, Jörger M, Henz S, Schmid H, Riesen W, Thomas G, Krek W, Cerny T, Gillessen Sommer S. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate cancer and prostatic diseases 2005; 8:316-20.
01.01.2005Hypertriglyceridemia as a possible risk factor for prostate cancer
01.01.2005Prostate cancer and prostatic diseases 2005; 8:316-20
Wuermli L, Jörger Markus, Henz Samuel, Schmid H-P, Riesen W F, Thomas G, Krek W, Cerny Thomas, Gillessen Sommer Silke
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
Engler H, Köberle D, Thürlimann B, Senn H, Riesen W. Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85.
01.11.1998Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease
01.11.1998Clinical chemistry and laboratory medicine : CCLM / FESCC 1998; 36:879-85
Engler H, Köberle Dieter, Thürlimann Beat, Senn H J, Riesen W F